Business Wire

HANSHOW

Share
Jumbo and Hanshow announce a new partnership to digitize over 700 stores

Jumbo, the second largest supermarket chain in the Netherlands which also has stores in Belgium, has announced an exclusive partnership with global retail solutions provider Hanshow to digitally transform its network of stores.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005660/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hanshow's electronic shelf labels (ESLs) installed at Jumbo (Photo: Business Wire)

Jumbo was founded in 1921 and currently owns more than 700 stores in the Netherlands and Belgium. It is locally renowned for its wide range of selections and personalized attention to both customers and employees.

With the digital transformation of its business model, Jumbo is becoming one of the leading retailers in Europe. This is driven in part by the Jumbo Tech Campus which facilitates the innovation of Jumbo’s digital solutions and channels to connect its online and offline retail business while strengthening relationships with customers.

The collaboration with Hanshow is a crucial move in Jumbo's digitization strategy. To date, Hanshow’s solutions have been rolled out in over 250 stores. Soon Jumbo will have upgraded all 700 of its stores, with over 11 million Hanshow electronic price tags installed.

“The unique Jumbo formula revolves around a large assortment with the best service at low prices. Correct prices on the shelf and the ability to react quickly and efficiently to market developments are essential for this. The technology of Hanshow contributes to this.” Jumbo said.

At the heart of this digital transformation with Hanshow, the adoption of over 11 million electronic shelf labels (ESLs) will save time and energy across all Jumbo stores. Hundreds of thousands of paper price tags can be saved by this partnership each year, which is also in line with Jumbo’s abiding goal of sustainability. ESLs dramatically increase efficiency for retail operations such as inventory management and faster order picking with LED flashing functions. Additionally, ESLs improve the customer shopping experience with centralized price updates, error-free labeling, and enhanced store appearance.

Powering the systems management of this massive amount of ESL is made possible by adopting the Hanshow SaaS solution via Microsoft Azure. Benefits for Jumbo include reducing costs spent on infrastructure and servers, and if needed the Hanshow technical support team is capable of helping resolve technical issues much faster. Hanshow’s PriSmart ESL and IoT device management system also allows Jumbo to get the systems up and running sooner and the ability to manage and update its pricing network in a faster, more secure, and more accessible way.

“Hanshow solutions can drive sustainability, improve efficiency, eliminate waste, and create new opportunities for Jumbo stores,” notes Sally Liang, General Manager of Europe, Hanshow. “This is an exciting era for retail, and we’re proud to be partnering with a company like Jumbo that is committed to improving its customer experience and operational efficiency through digital retail transformation.”

The cooperation with Jumbo is a significant achievement for Hanshow’s international development. In the future, Hanshow looks forward to cooperating with global customers to further explore the paths of digital transformation, to further optimize digital store solutions, and to provide more comprehensive, intelligent, and efficient digital service upgrades.

About Hanshow
Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions, offering global customers a series of world-class customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow’s solutions are used by over 30,000 stores in more than 50 countries, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005660/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye